SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9100)3/11/1999 12:44:00 AM
From: aknahow  Respond to of 17367
 
Bluegreen, I have no idea where the 125 came from. It was 200.

From XOMA FAQ's earlier version 1997.
 
"What was the result of the meningococcemia DSMB meeting May 30,
1997?
At the meeting, they decided certain administrative matters,
ratified the size (200 patients) and design of the trial,
announced increments for interim analyses (65 and 130
patients), and asked us to not disclose the number of deaths."

Note at this point they had not yet accrued the first 65 patients.

This does not change my opinion that the thrust of his argument still holds. Holds even better with 200 since the number of deaths based on 125 would be so low as to be impossible.
 



To: Bluegreen who wrote (9100)3/11/1999 10:14:00 AM
From: Bluegreen  Read Replies (2) | Respond to of 17367
 
SL, so when you are saying "close" you mean to mortality requirement not close enough for government work? Castello said close to mortality requirement number which in my opinion is not the same as close to ending trial. Or let me ask you a simple question, what do you think happens if mortality number is not reached by this summer?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News